AU2012203517B2 — Salts of potassium ATP channel openers and uses thereof
Assigned to Soleno Therapeutics Inc · Expires 2014-04-24 · 12y expired
What this patent protects
Provided are immediate or prolonged administration of certain salts of KATp channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, 5 pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditi…
USPTO Abstract
Provided are immediate or prolonged administration of certain salts of KATp channel openers such as diazoxide to a subject to achieve novel pharmacodynamic, 5 pharmacokinetic, therapeutic, physiological, metabolic and compositional outcomes in the treatment of diseases or conditions involving KA-rP channels. Also provided are pharmaceutical formulations, methods of administration and dosing of the salts that achieve these outcomes and reduce the incidence of adverse effects in treated individuals. Further provided are method of co-administering the salts with other drugs 10 to treat diseases of humans and animals.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.